
Matthew J Betts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3755565/publications.pdf Version: 2024-02-01



Μλττμενν I Retts

#	Article	IF	CITATIONS
1	Associations among locus coeruleus catecholamines, tau pathology, and memory in aging. Neuropsychopharmacology, 2022, 47, 1106-1113.	5.4	27
2	Localization of the Locus Coeruleus in MRI via Coordinate Regression. Informatik Aktuell, 2021, , 10-15.	0.6	2
3	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. Brain, 2021, 144, 2732-2744.	7.6	57
4	Current challenges in reliably targeting the noradrenergic locus coeruleus using transcutaneous auricular vagus nerve stimulation (taVNS). Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102900.	2.8	19
5	Fully automated deep learning-based localization and segmentation of the locus coeruleus in aging and Parkinson's disease using neuromelanin-sensitive MRI. International Journal of Computer Assisted Radiology and Surgery, 2021, 16, 2129-2135.	2.8	8
6	CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.8	0
7	A proposition for analyses and reporting standards for structural and functional magnetic resonance imaging of the noradrenergic locus coeruleus. Alzheimer's and Dementia, 2021, 17, .	0.8	0
8	Quantitative R1 in the locus coeruleus in Alzheimer's disease dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
9	Automated segmentation of the locus coeruleus in aging and Alzheimer's disease using 3T neuromelanin-sensitive MRI Alzheimer's and Dementia, 2021, 17 Suppl 3, e052564.	0.8	0
10	The Role of the Striatum in Learning to Orthogonalize Action and Valence: A Combined PET and 7ÂT MRI Aging Study. Cerebral Cortex, 2020, 30, 3340-3351.	2.9	7
11	Learning in anticipation of reward and punishment: perspectives across the human lifespan. Neurobiology of Aging, 2020, 96, 49-57.	3.1	11
12	Functional indicators of a decline in the noradrenergic locus coeruleus in ageing. Alzheimer's and Dementia, 2020, 16, e044582.	0.8	0
13	In vivo locus coeruleus imaging in Alzheimer's and Parkinson's disease. Alzheimer's and Dementia, 2020, 16, e044587.	0.8	0
14	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	6.2	42
15	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	6.2	96
16	Older adults show a reduced tendency to engage in context-dependent decision biases. Neuropsychologia, 2020, 142, 107445.	1.6	3
17	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. Nature Communications, 2020, 11, 1712.	12.8	74
18	International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020). Frontiers in Human Neuroscience, 2020, 14, 568051.	2.0	143

MATTHEW J BETTS

#	Article	IF	CITATIONS
19	Automated Segmentation of the Locus Coeruleus from Neuromelanin-Sensitive 3T MRI Using Deep Convolutional Neural Networks. Informatik Aktuell, 2020, , 61-66.	0.6	5
20	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	7.6	219
21	Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF AÎ ² levels. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 281-285.	2.4	56
22	InÂvivo visualization of age-related differences in the locus coeruleus. Neurobiology of Aging, 2019, 74, 101-111.	3.1	117
23	Locus coeruleus integrity in old age is selectively related to memories linked with salient negative events. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2228-2233.	7.1	104
24	F4â€07â€03: RELATIONSHIP BETWEEN LOCUS COERULEUS MRI CONTRAST, COGNITION AND CSF BIOMARKERS AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1393.	IN 0.8	0
25	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	2.4	26
26	Commentary: Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. Frontiers in Neuroscience, 2018, 12, 401.	2.8	7
27	In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. NeuroImage, 2017, 163, 150-159.	4.2	117
28	[P3–395]: USING NEUROMELANIN ENSITIVE MRI TO CHARACTERISE THE STRUCTURAL INTEGRITY OF THE HUMAN LOCUS COERULEUS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1114.	0.8	0
29	[P2–074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634.	0.8	0
30	Emotional arousal and recognition memory are differentially reflected in pupil diameter responses during emotional memory for negative events in younger and older adults. Neurobiology of Aging, 2017, 58, 129-139.	3.1	20
31	The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease. Brain, 2017, 140, 118-131.	7.6	154
32	High-resolution characterisation of the aging brain using simultaneous quantitative susceptibility mapping (QSM) and R2* measurements at 7 T. NeuroImage, 2016, 138, 43-63.	4.2	101
33	<i>In Vivo</i> MRI Mapping of Brain Iron Deposition across the Adult Lifespan. Journal of Neuroscience, 2016, 36, 364-374.	3.6	217
34	Midbrain fMRI: Applications, Limitations and Challenges. Biological Magnetic Resonance, 2015, , 581-609.	0.4	11
35	Allosteric modulation of the group III mGlu ₄ receptor provides functional neuroprotection in the 6â€hydroxydopamine rat model of Parkinson's disease. British Journal of Pharmacology, 2012, 166, 2317-2330.	5.4	55
36	Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. British Journal of Pharmacology, 2012, 165, 1034-1045.	5.4	40

#	Article	IF	CITATIONS
37	Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. British Journal of Pharmacology, 2010, 160, 1741-1753.	5.4	44